Since human endothelial cells synthesize Factor V but do not secrete It into the medium, we studied the effects of cell Injury on the availability of Factor V at the surface of these cells. Human umbilical vein endothelial cells (HUVEC), grown to confluency and Incubated with human 125 I Factor Va, specifically bound 5000 to 7000 molecules per cell. In the absence of added Va, no antigen was detected on adherent HUVEC with either labeled antl-V(Va) monoclonal or polyclonal IgG. However, exogenous Va, not V, prebound to these cells allows binding of labeled 125 I antl-V(Va). Immunodectectibillty of bovine Factor V contributed by fetal calf serum In the concentration used in cultures is less than 0.1% of that detected in human plasma. HUVEC, suspended by scraping from dishes, specifically bound 4000 molecules/cell of 125 /l monoclonal IgG against V(Va). Although undisturbed cells excluded trypan blue, dye uptake by many of the suspended HUVEC Indicated cell Injury. Quantitatlon of injury by 51 Cr release after scraping followed by multiple passages through an 18 g needle showed that 51 Cr release Increased with number of manipulations up to 60% and was observed almost immediately after manipulation. We suggest that little Factor V(Va) is present on the surface of intact adherent HUVEC. However, mechanical Injury to HUVEC released or exposed endogenous Factor V(Va), resulting In expression of V that might mediate Factor Xa binding as well as activation of protein C by thrombin. Thus, injured, but not Intact, HUVEC could participate in both promoting and limiting blood coagulation. (Arteriosclerosis 6
T he endothelial lining of blood vessels is a nonthrombogenic surface that helps to maintain blood fluidity. However, injury to vascular endothelium initiates the hemostatic process, which in pathological conditions may lead to thrombosis. Endothelial cells synthesize a variety of proteins such as plasminogen activator, 1 thromboplastin, 2 collagen, 3 fibronectin, 4 and Factor Vlllvwf. 5 In addition, these cells interact with plasma proteins such as a 2 macroglobulin, 6 protein C, 7 and thrombin. 8 Potent antithrombotic activity of endothelial cells includes synthesis and release of prostacyclin which inhibits platelet activation, 9 rapid inactivation of thrombin by Antithrombin III catalyzed by sulfated glycosaminoglycans present on the cell surface, 10 inhibition of thrombin-catalyzed fibrin formation by complex formation between thrombin and thrombomodulin, 11 and acceleration of protein C activation by the cofactor thrombomodulin. 7 Activated protein C in turn promotes inactivation of Factors Va 12 and Villa 13 and stimu-lates release of fibrin-dependent vascular plasminogen activator. 14 The coagulant activities of endothelium leading to the formation of thrombin have only recently been studied. These studies include activation and interaction of coagulation factors such as XII, 15 VII, 16 IX, 17 ' 18 X, 19 and prothrombin. 20 Bovine aortic endothelial cells synthesize Factor V 21 and secrete it into the medium. In contrast, HUVEC synthesizes Factor V but fails to secrete it into the medium. 22 ' a In this paper, we report that although human Factor V a binds to HUVEC, it is not expressed on intact adherent cells. In contrast, injury to HUVEC can cause expression or exposure of Factor Va activity, presumably on the cell surface.
Methods Materials
The medium and the chemicals for tissue culture were purchased from Gibco Company, Grand Island, New York. Purified human thrombin (3209 NIH units/mg) was a gift from Dr. John Fenton, New York State Department of Health. Bovine serum, collagenase, and trypsin II were obtained from Sigma. D-phenyl-alanyl-L-prolyl-L-arginine chloromethyl ketone: 2HCL:3H 2 O (PPACK) was obtained from Calbiochem, Behring Corporation, La Jolla, California. Other chemicals were of the best reagent grade. 125 
Methods

Factor V
Human plasma Factor V was purified as described by Chiu et al. 24 It showed a single band with a M, of 330,000 on both reduced and nonreduced SDS gel electrophoresis. The specific activity ranged from 70 to 100 units per mg and increased 20-to 25-fold on exposure to thrombin.
Preparation of Rabbit Polyclonal Antihuman Factor V(Va) IgG
The antibody was prepared as previously described. 24 It was monospecific as judged by immunodiffusion and immunoelectrophoresis, and it neutralized plasma and purified Factor V. The crossreaction with bovine plasma was less than 1%.
Preparation of Mouse Monoclonal Antihuman Factor V(Va)
Purified human Factor V (75 /^g) was injected intraperitoneally into 3-to 4-month-old BALB-c mice with complete Freund's adjuvant. These mice were boosted with 50 /xg of Factor V in saline after 14 days. The spleens were removed from immunized mice 3 days later and used for fusion with mouse myeloma cells. 25 The cells were cloned by limiting dilution, and the culture media was tested for antifactor V(Va) antibody by use of ELISA or Factor V neutralizing assay. 24 Cells producing such antibodies were redoned and propagated in the ascites of mice primed with pristane. One clone produced a monoclonal (lgG,,K) antibody (B.38) that neutralized Factor V at a titer of 1:12,800. This monoclonal antifactor V (B.38) was purified by precipitation with 33% ammonium sulfate and by chromatograiphy of the precipitate (resuspended in 0.02 M Tris-CI, pH 7.4, containing 0.15M NaCI) on DEAE column.
Assay of Factor V Activity
The coagulant activity of Factor V was assayed by the method of Ware et al. 26 by using artificially deficient human plasma. 27 One unit of Factor V is defined as the amount of activity in 1 ml of normal human plasma.
Protein Concentration
Protein was measured either by the Bio Rad protein assay 28 or by the spectrophotometric method with the following values for A 1% IgG,14.3; Factor V.9.6.
Radioiodination of Proteins
Human Factor V, mouse monoclonal, and rabbit polyclonal antihuman Factor V IgG were radiolabeled with 12S I by the iodogen method, and free 12S I was removed rapidly as described by Tuszynski et al. 29 The specific radioactivity of the labeled Factor V ranged from 7.0 to 9.0 x 10® cpm per fig, monoclonal antifactor V, 5.0 to 6.0 x 10 8 cpm per HQ, and polyclonal antifactor V, 4.0 x 10 6 cpm per ^tg. The iodination procedure did not alter either the specific coagulant activity of Factor V or its proteolytic activation by thrombin.
Thrombin Activation of 125 I Factor V
Radiolabeled Factor V (1 to 2 units/ml) was incubated with thrombin (0.05 to 0.1 unit/ml) in buffer (0.02M Tris and 0.15M NaCI, pH 7.4) containing 1% BSA at room temperature for 30 minutes. The coagulant activity increased 15-to 30-fold after incubation. The action of thrombin was stopped by the addition of PPACK, 4-8 x l O^M . 3 0 When the digest was subjected to SDS electrophoresis, four polypeptides, M r = 150,000 (C1), M r = 105,000 (D), M r = 74-71000 (F1F2), and M r = 40,000, were observed in agreement with Dahlback. 31 
Specificity of the Monoclonal Antibody B.38
The purified antibody was immobilized to produce an immunoaffinity column as described before. 24 The column was equilibrated with 0.02 M Tris buffer (pH 7.2) containing 0.15 M NaCI. The radiolabeled thrombin-digested Factor V containing 0.02M EDTA was applied to the column and washed with 0.02M Tris buffer (pH 7.2) containing 0.36M NaCI and again the same buffer containing 0.15M NaCI and 5% glycerol. Specifically bound Factor Va was then eluted with the same buffer containing 25% glycerine and 50% ethylene glycol. The wash contained Cl, D, and M r 40,000 polypeptides. The ethylene glycol-glycerine eluate contained the Factor Va light chain, M r = 74-71000 (F1F2). Thus, the epitope binding specificity for B.38 was found in the light chain.
Human Umbilical Vein Endothelial Cell Culture
Endothelial cells (HUVEC) were harvested and grown essentially by the method of Jaffe et al. 32 Cells were plated in 35 mm dishes precoated with human fibronectin (50 /xg/ml) with Dulbecco's modified Eagles medium (DMEM) plus 20% fetal bovine serum and endothelial cell growth supplement (150 /ig/ml final concentration). Cells were subcultured at a 1 -2 split ratio by using trypsin and EDTA, and were replated in fibronectin-coated dishes with the same medium. Fetal calf serum in the concentration used gave less than 0.1% crossreactrvity in a Factor V ELISA compared to human plasma.
The number of cells per dish was determined by removing and dispersing the layers with 0.1% trypsin plus 0.1% EDTA and by counting aliquots of the cell suspension by phase microscopy. The cell number was determined periodically on three dishes taken at random. Two counts were done on each dish, and the six values were used to give an average cell count. The variability was usually not more than 10%.
Binding of 125 I Factor Va to Adherent HUVEC
Binding of labeled Factor V was carried out by using monolayers of cells in 35 mm dishes (1 x 10 6 cells/dish). Serum-containing medium was aspirated, and cultures were washed once with 1 ml of serum-free medium. 125 I Va in 1 ml of serum-free medium containing 1% BSA was added and incubated at 37° C for 30 minutes in a 5% CO 2 atmosphere. At the end of the incubation, medium containing labeled Va (supernatant) was transfered by pipette to a test tube (75 x 12 mm) for measurement for radioactivity. The cultures were then washed twice with 1 ml of serumfree medium, which removed 99.7% of the unbound radioactivity as measured with 12S I BSA. The cells were then removed with a rubber policeman and solubilized with 1.5 ml of 0.015M Tris (pH 7.4) containing 0.15M NaCI, 0.01 M EDTA, and 0.025% Triton X-100 (wt/vol) (solublizing buff-er). The radioactivity of supernatant and cells was measured by Gamma Counter Nuclear Enterprises NE 1600 or LKB 1270 Rack Gamma 11.
Binding of Labeled Mouse Monoclonal Antifactor V(Va) IgG to HUVEC in Suspension
Serum-containing medium was removed from cultures by aspiration. Cells were washed once with 1 ml of serumfree medium. Then 1 ml of medium was added to the cells, and they were scraped off the dishes with a rubber policeman. The suspension was transferred to 75 x 12 mm test tubes. The dishes were rinsed with 2 ml of medium which was added to the cell suspension for a total volume of 3 ml. Cells were centrifuged at 800 rpm for 10 minutes with a table top centrifuge (IEC Centra 7R). About 2.5 ml of the supernatant was carefully pipetted out without disturbing the cells and was discarded. The cells in 0.5 ml of the medium were resuspended and dispersed by gently passing them five times through an 18 g needle. To this suspension was added 1 ml of labeled or a mixture of labeled and 50-to 100-fold excess of unlabeled antifactor V IgG (B.38). HUVEC with antifactor Va were returned to the incubator. At the end of the incubation, the cell suspensions were transferred to Eppendorf tubes and centrifuged for 2 minutes; the supernatant was saved for counting. The cells were washed twice with 1 ml of ice-cold medium and were centrifuged as explained above; the supernatant was removed. The radioactivity was counted as described before.
Binding of Labeled Mouse Monoclonal Antifactor V(Va) IgG to Adherent Monolayers of HUVEC
Serum-containing medium was removed, and HUVEC was washed twice with 1 ml of ice-cold serum-free medium. This was followed by the addition of 1 ml of labeled or a mixture of labeled and 50-to 100-fold excess of unlabeled monoclonal IgG. The dishes were incubated at 37° for 30 minutes as before. At the end of the incubation, antifactor V(Va), B.38, was removed by aspiration. The monolayers were washed twice with 1 ml of ice-cold serum-free medium. The cells were scraped off with a rubber policeman in 1 ml of solubilizing buffer and the radioactivity was counted.
The binding of 125 I rabbit polyclonal antifactor V(Va) IgG to adherent monolayers of HUVEC was measured by the same procedure.
Binding of 125 I Anti-V(Va) to Adherent Monolayers of HUVEC-Containing, Prebound Unlabeled Factor Va orV
Monolayers of the cells were washed with 1 ml of serumfree medium. An aliquot (1.6 jig) of unlabeled Factor Va or V in 1 ml of serum-free medium containing 1 % BSA was added and was incubated at 37° C for 30 minutes in a 5% CO 2 atmosphere. At the end of this incubation, the medium with unbound Va or V was aspirated and cells were washed twice with serum-free medium. The cells then were incubated with 1 ml of labeled or a mixture of labeled and 50-to 100-fold excess of unlabeled monoclonal anti-V(Va). The cells were incubated at 37°C for 30 minutes as before. At the end of the incubation, unbound antifactor V in the medium was removed by aspiration, and monolayers were washed twice as described earlier. The cells were scraped off in 1 ml of solubilizing buffer and the radioactivity was counted.
Assessment of Endothelial Cell Injury
HUVEC injury as a consequence of physical manipulations was estimated by trypan blue exclusion and quantified by release of 51 Cr. For trypan blue exclusion, the medium was removed and the cells were washed twice with Tyrode's solution. For the control, 1 ml of Tyrode's solution and 25 fi\ of trypan blue (0.4%) were added to adherent cells and the cells were observed for 10 minutes, at which time representative fields were photographed. To estimate the effects of manipulation, washed cells were scraped off the dish with a rubber policeman, were passed through an 18 g needle five times, and were sedimented by slow centrifugation (800 rpm, 150 g). The supemate was removed, and the pellet was resuspended in 1 ml of Tyrode's solution. Trypan blue was added to aliquots of the cell suspension and was .examined and photographed immediately and after 10 minutes.
The release of cytoplasmic components was quantified by labeling confluent monolayers of cells with 61 Cr and counting the amount of radioactivity released to the medium after various manipulations. s1 Cr (12 mCi, specific activity 300 mCi/mg) as sodium chromate in normal saline was added to 75 ml of serum-free medium. The medium was removed, the cultures were washed twice with serumfree medium, and 1 ml of 51 Cr was added to each dish. After 30 minutes at room temperature, the radioactive medium was removed and the cultures were washed twice with serum-free medium. All cultures were returned to the incubator until used. Manipulations included cells left undisturbed (base-line), cells scraped off the dish with a rubber policeman, and cells scraped off the dish and passed through an 18 g needle once, five times, or 10 times. The time course of release of radioactivity was determined by preparing supernates for counting of released radioactivity at 0, 5, 10, 20 and 40 minutes after each of these treatments. Supernates were prepared by sedimenting the cells in an Eppendorf centrifuge. Radioactivity remaining within the cells was measured after lysing the cells with solublizing buffer.
Results
Binding of 12S I Human Factor Va to Adherent HUVEC
The binding of radiolabeled exogenous Factor Va to monolayers of adherent cells was rapid and attained equilibrium within 10 minutes. Factor Va (5000-7000 molecules per cell) bound specifically at 37°C ( Figure A) . The inclusion of 50-fold excess of unlabeled Factor Va resulted in a marked decrease in the binding of 125 I Factor Va (0.2-0.6 /xg) to about 60% of maximum (Figure 1 A) . At higher concentrations of added labeled Factor Va, nonspecific binding became higher than specific binding. A Scatchard plot 33 of binding of Factor Va to HUVEC (Figure  1 B) 
Binding of 12S I Labeled Mouse Monoclonal Antifactor V(Va) IgG to Monolayers of HUVEC
No specific binding to adherent monolayers of the monoclonal antibody to Factor Va could be demonstrated (Figure 2) , indicating that no detectable Factor V was expressed on the surface of the endothelial cells. A 50-fold excess of unlabeled antibody failed to decrease the binding of radiolabeled antifactor V(Va), showing an almost complete absence of specific binding (Figure 2 ).
Binding of Labeled 125 I Rabbit Polyclonal Antlfactor V(Va) IgG to Monolayers of HUVEC
The failure of the monoclonal antibody to bind to adherent endothelial cells might have been due to the lack of expression of the epitope recognized rather than to the failure of binding. Therefore, rabbit polyclonal antibody was also used in binding studies. Inclusion of a 50-fold excess of unlabeled polyclonal antibody did not decrease the binding of labeled polyclonal antibody as shown on Table 1 , thus confirming the virtual absence of Factor V(Va) antigen on the cell surface.
Binding of 12B I Labeled Monoclonal Antl-V(Va) to Monolayers of HUVEC Exposed to Exogenous Factor Va or V
Since adherent cells did not bind labeled anti-V(Va), as shown in Figure 2 , we investigated whether adherent cells -* -* HUVEC were cultured as described In methods. 1 ml of labeled 125 I Antlfactor V(Va) in serum-free medium was added to cells in 35 mm dishes and incubated for 30 minutes at 37° C in a 5% C 0 2 incubator. Total, nonspecific, and specific bindings were measured as described In methods. Each value represents the mean + so of five determinations.
T h e differences between total and nonspecific binding were not significant (p > 0.1).
to which exogenous Factor Va or V was added could then bind the antibody. At a concentration of 1. 6 fig of added labeled Va, the cells bound specifically 0.82 ng of Va (Figure 1 A) . When the cells were preincubated with 1.6 /xg of unlabeled Va, radiolabeled 125 I antj-V(Va) was bound specifically. The total binding of anti-V was 12017 ±740 cpm (mean and SD of triplicate determinations), while the nonspecific binding was 9626 ±310 cpm (mean and SD of triplicate data). Thus, the specific binding was 2391 cpm, equivalent to 0.85 ng of antibody. No binding of labeled anti-V(Va) was observed when the cells were preincubated with 1.6 /xg of unlabeled Factor V. 
Production and Quantification of Cytolytlc Cell Injury
Since the initiation of thrombosis involves damage to blood vessels and detachment of the adherent endothelial cells from the basement membrane, we sought to simulate this process in vitro. The mechanical removal of endothelial cells from their substrate induced considerable cell injury and further cell lysis resulting from the passage of the cells through an 18g needle. It was immediately obvious that essentially all adherent cells excluded trypan blue. On the other hand, we were unable to obtain an accurate estimate of the percentage of suspended cells that excluded or took up the dye. Even after passage through the needle, a large percentage of the cells remained in sizable, often partially scrolled, clumps making visualization of part of the cells impossible. However, it was obvious that many cells in large clumps excluded dye while most single cells and small clumps took up the dye. It appeared that slow centrtfugatJon reduced but did not eliminate the number of single cells and small clumps in the pellet.
Quantification of cell injury by release of 51 Cr showed that release was only 5% in adherent cells but was about 50% in cells scraped off the dish and about 60% after passage through an 18 g needle (Figure 3 ). 
Binding of 125 I Mouse Monoclonal Antifactor V(Va) to Detached HUVEC
Discussion
Several recent studies have suggested that the endothelium participates in the regulation of localized coagulation such as might occur in response to vessel wall injury or in atherosclerosis and thrombosis. 17 " 19 Bovine aortic endothelial cells markedly accelerated the conversion of prothrombin to thrombin in the presence of added human Factor Xa and calcium, implying that human Factor Xa binds to these cells. 20 Since this activity required no exogenous Factor V and was inhibited by an antifactor V antibody, Rodgers and Shuman 20 concluded that endogenous Factor V was available. The synthesis and release of Factor V by bovine aortic cells was shown by Cerveny et al. 21 Unlike bovine endothelial cells, human endothelial cells from umbilical veins fail to secrete Factor V into the medium. 22 -M Thus, there is no extracellular source for Factor V.
The study of Rodgers and Shuman 20 implied that Factor V was available on the cell surface and functioned in the assembly of the prothrombinase complex on bovine aortic cells. Two studies have been concerned directly with the presence and role of Factor V in the regulation of coagulation by HUVEC. Sinha et al. 22 from our laboratory recently reported that cultured human umbilical vein endothelial cells contained, but did not secrete, Factor V into the medium. They found that 200 molecules of Factor Xa bound to each endothelial cell in a monolayer resulted in the downregulation of production of PGI 2 . This functional effect of Xa is blocked by anti-V, indicating that endogenous Factor V is required. Maruyama et al. 34 reported the binding of radiolabeled antifactor V(Va) to cells that had been removed from the substrate and passed through a 19 g needle. These cells also accelerated the activation of protein C.
While both of these studies suggested that Factor V(Va) was available on the cell surface, we were unable to detect Factor V on the surface of adherent monolayers of HUVEC in extensive studies with radiolabeled monoclonal and polyclonal antibodies ( Figure 2 and Table 1 ). In contrast, removal and suspension of HUVEC resulted in the binding of 4000 molecules per cell of radiolabeled IgG per cell (Figure 2 A) , implying an equal number of exposed Factor V(Va) molecules. This is in agreement with the observation of Maruyama et al. 34 In addition, we found that the appearance of Factor V(Va) molecules that were accessible to antifactor V(Va) antibody closely parallel cell injury and death as measured by release of 51 Cr. This finding suggests that endogenous Factor V(Va) had been made available possibly through release from damaged cells with consequent binding to intact cells. It is equally possible that Factor V in dead cells is capable of binding the antibody as has been shown by the binding of IgG to dead cells. 35 We also showed that binding of 125 l-labeled Factor Va to HUVEC was specific and saturable ( Figure 1) .
The apparent discrepancies between our study and the studies of Rodgers and Shuman, 20 Sinha et al., 22 and Maruyama et al. 34 necessitate a close examination of all four studies. Indirect evidence for the presence of Factor V on the surface of bovine aortic and human umbilical vein endothelium in the functional studies of Rodgers and Shuman and Sinha et al. and our inability to demonstrate Factor V by binding studies can be explained by the greater sensitivity of the functional studies through amplification by product formation. It should be noted that the presence of less than 500 molecules of endogenous Factor V per cell would not have been apparent in our monoclonal antibody binding studies. The observation by Maruyama 34 of less cell damage (70% to 90% of cells excluded trypan blue) than we found (50% to 60% release of 51 Cr) apparently depended on differences in technique, since 51 Cr is more easily quantified than trypan blue. We included all cells in our estimate of damage while they considered only those cells remaining in the pellet after centrifugatjon at 800 rpm (probably about 150 fif). Suspension of endothelial cells apparently leads to cytolytic damage or death which should be considered by investigators using this model to study the interaction of procoagulant proteins with endothelial cells.
Based on our observations, we suggest that human endothelial cells not only bind exogenous Factor V but also express or expose endogenous Factor V activity upon mechanical injury. This observation is of relevance to several clinical situations in which blood vessels are directly injured by mechanical means such as endarterectomy, construction of arterial bypasses, and various forms of catheterization. Other examples of cytotoxic injury occurring in pathologic conditions include the effects of circulating antigen-antibody complexes which activate complement, endotoxin, and cytotoxic viruses.
Undisturbed adherent HUVEC express little Factor V on their surface, consistent with their role in maintaining blood fluidity and a nonthrombogenic surface for flowing blood. The exposure of Factor V after endothelial injury or death may play an important role in pathological thrombogenesis.
